CD253 (TRAIL) Monoclonal Antibody (N2B2), Functional Grade, eBioscience™, Invitrogen™

Description

• Description: The N2B2 monoclonal antibody reacts with mouse TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily
• TRAIL is not detected on the surface of freshly isolated T, B, or NK cells, but can be induced preferentially on CD3^- NK1.1^+ NK cells after stimulation with IL-2 or IL-15
• N2B2 inhibits IL-2- or IL-15-activated NK cell cytotoxicity against mouse fibrosarcoma L929 target cells
• Applications Reported: N2B2 has been reported for use in flow cytometric analysis, and blocking of TRAIL in functional assays
• Applications Tested: The N2B2 antibody has been tested by flow cytometric analysis of mouse TRAIL transfected cells and can be used at less than or equal to 1 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Storage and handling: Use in a sterile environment
• Filtration: 0.2 μm post-manufacturing filtered
• Purity: Greater than 90%, as determined by SDS-PAGE
• Endotoxin Level: Less than 0.001 ng/μg antibody, as determined by LAL assay
• Aggregation: Less than 10%, as determined by HPLC
• TRAIL is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family
• TRAIL preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues
• TRAIL binds to several members of TNF receptor superfamily including TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and possibly also to TNFRSF11B/OPG
• The activity of this protein may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and TNFRSF11B/OPG that cannot induce apoptosis
• The binding of TRAIL protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3
• Receptors for TRAIL include two death domain containing receptors, death receptor 4 (DR4) and DR5, as well as two decoy receptors, DcR1 and DcR2, lacking the intracellular signaling death domain
• TRAIL is a type II membrane protein and expressed in a variety of human tissues
• Like TNF and Fas ligand, TRAIL induces apoptosis and NF-kB activation in many tissues and cells.